ITMI20110771A1 - COMPOSITION INCLUDING AN ASSOCIATION OF VITAMINS FOR USE IN THE TREATMENT OF ALGODISTROFIA. - Google Patents
COMPOSITION INCLUDING AN ASSOCIATION OF VITAMINS FOR USE IN THE TREATMENT OF ALGODISTROFIA. Download PDFInfo
- Publication number
- ITMI20110771A1 ITMI20110771A1 IT000771A ITMI20110771A ITMI20110771A1 IT MI20110771 A1 ITMI20110771 A1 IT MI20110771A1 IT 000771 A IT000771 A IT 000771A IT MI20110771 A ITMI20110771 A IT MI20110771A IT MI20110771 A1 ITMI20110771 A1 IT MI20110771A1
- Authority
- IT
- Italy
- Prior art keywords
- composition
- vitamin
- compound
- use according
- calcium
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 39
- 229940088594 vitamin Drugs 0.000 title description 4
- 229930003231 vitamin Natural products 0.000 title description 4
- 235000013343 vitamin Nutrition 0.000 title description 4
- 239000011782 vitamin Substances 0.000 title description 4
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 claims description 32
- 150000001875 compounds Chemical class 0.000 claims description 22
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 22
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 20
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 20
- 239000011575 calcium Substances 0.000 claims description 20
- 229910052791 calcium Inorganic materials 0.000 claims description 20
- 235000005282 vitamin D3 Nutrition 0.000 claims description 20
- 239000011647 vitamin D3 Substances 0.000 claims description 20
- 229940021056 vitamin d3 Drugs 0.000 claims description 20
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 18
- 239000011777 magnesium Substances 0.000 claims description 18
- 229910052749 magnesium Inorganic materials 0.000 claims description 18
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 claims description 18
- 235000019143 vitamin K2 Nutrition 0.000 claims description 18
- 239000011728 vitamin K2 Substances 0.000 claims description 18
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 17
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims description 15
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims description 15
- 235000009464 menaquinone-7 Nutrition 0.000 claims description 14
- 239000011700 menaquinone-7 Substances 0.000 claims description 14
- RAKQPZMEYJZGPI-LJWNYQGCSA-N menaquinone-7 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 RAKQPZMEYJZGPI-LJWNYQGCSA-N 0.000 claims description 11
- PFRQBZFETXBLTP-RCIYGOBDSA-N 2-[(2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl]-3-methyl-1,4-dihydronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-RCIYGOBDSA-N 0.000 claims description 10
- -1 granular Substances 0.000 claims description 7
- 241000195493 Cryptophyta Species 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 229940124641 pain reliever Drugs 0.000 claims description 3
- 238000009109 curative therapy Methods 0.000 claims description 2
- 235000005911 diet Nutrition 0.000 claims description 2
- 230000000378 dietary effect Effects 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims description 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 230000008733 trauma Effects 0.000 description 6
- 210000003423 ankle Anatomy 0.000 description 3
- 230000033558 biomineral tissue development Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 210000000707 wrist Anatomy 0.000 description 3
- 206010024453 Ligament sprain Diseases 0.000 description 2
- 208000010040 Sprains and Strains Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000018678 bone mineralization Effects 0.000 description 2
- 238000005115 demineralization Methods 0.000 description 2
- 230000002328 demineralizing effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 108010087765 Antipain Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000230999 Lithothamnion Species 0.000 description 1
- 206010065016 Post-traumatic pain Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
Description
DESCRIZIONE DESCRIPTION
"Composizione comprendente un'associazione di vitamine per uso nel trattamento dell 'algodistrofia" . "Composition comprising a combination of vitamins for use in the treatment of algodystrophy".
La presente invenzione si riferisce a una composizione comprendente un'associazione di vitamine per uso nel trattamento dell 'algodistrofia . In particolare, la presente invenzione si riferisce a una composizione comprendente un'associazione di vitamine e una fonte biodisponibile di calcio e/o magnesio per il trattamento dell'algodistrofia . The present invention relates to a composition comprising an association of vitamins for use in the treatment of algodystrophy. In particular, the present invention relates to a composition comprising an association of vitamins and a bioavailable source of calcium and / or magnesium for the treatment of algodystrophy.
L'algodistrofia, anche conosciuta come "sindrome complessa del dolore regionale" e' una sindrome multisintomatica e multisistemica che può'affliggere un'estremità traumatizzata ma che può localizzarsi anche in altre parti del corpo. Algodystrophy, also known as "complex regional pain syndrome" is a multisymptomatic and multisystemic syndrome that can affect a traumatized extremity but can also be localized in other parts of the body.
L'algodistrofia e' stata descritta molti anni orsono, ma le sue vere cause rimangono ancora oggi non del tutto comprese e chiarite. Algodystrophy was described many years ago, but its true causes still remain not fully understood and clarified today.
L'algodistrofia, nota anche come Atrofia di Sudeck, provoca una condizione di forte dolore. Viene utilizzato anche il nome "distrofia da riflesso simpatico" per evidenziare l'importanza del sistema nervoso simpatico nella patologia del dolore post-traumatico. Algodystrophy, also known as Sudeck's Atrophy, causes a severe pain condition. The name "sympathetic reflex dystrophy" is also used to highlight the importance of the sympathetic nervous system in the pathology of post-traumatic pain.
L'algodistrofia di Sudeck à ̈ una decalcificazione dell'osso loco-regionale. La causa scatenante può essere dovuta a un trauma che si verifica a seguito di una frattura o una distorsione ad esempio del piede, caviglia o polso. A seguito del trauma, il paziente deve sottostare ad una immobilizzazione o ad un periodo di inattività molto lungo con una conseguente disfunzione neurologica ai danni della parte del corpo interessata. La conseguenza dell'immobilizzazione post-frattura del piede, caviglia o polso à ̈ una riduzione fino al 20% della densità minerale ossea. All'esame radiografico si evidenzia una rarefazione delle trabecole ossee. La demineralizzazione causa un dolore profondo, molto forte, continuo e sproporzionato rispetto all'entità del trauma subito. Molto spesso il dolore si manifesta anche a riposo nella zona interessata al trauma. Per ridurre il dolore viene indicata la somministrazione dì farmaci che aumentano il metabolismo osseo e farmaci anti-dolorifici o anti-infiammatori non steroidei (FANS). Tuttavia, la somministrazione di questi farmaci non à ̈ sempre tollerata e, comunque, non à ̈ priva di inconvenienti. Inoltre, non sempre si riesce a trattare con successo l'algodistrofia mediante la somministrazione di detti farmaci. Sudeck's algodystrophy is a decalcification of the loco-regional bone. The triggering cause can be due to a trauma that occurs as a result of a fracture or a sprain, for example, of the foot, ankle or wrist. Following the trauma, the patient must undergo an immobilization or a very long period of inactivity with a consequent neurological dysfunction which damages the affected part of the body. The consequence of post-fracture immobilization of the foot, ankle or wrist is a reduction of up to 20% in bone mineral density. Radiographic examination shows a rarefaction of the bone trabeculae. The demineralization causes a deep pain, very strong, continuous and disproportionate to the extent of the trauma suffered. Very often the pain occurs even at rest in the area affected by the trauma. To reduce pain, the administration of drugs that increase bone metabolism and non-steroidal anti-pain or anti-inflammatory drugs (NSAIDs) is indicated. However, the administration of these drugs is not always tolerated and, in any case, it is not without drawbacks. Furthermore, it is not always possible to successfully treat algodystrophy by administering said drugs.
Forma oggetto della presente invenzione una composizione comprendente una vitamina K2 in associazione con una vitamina D3per uso nel trattamento dell'algodistrofia. The present invention relates to a composition comprising a vitamin K2 in association with a vitamin D3 for use in the treatment of algodystrophy.
Forme preferite della presente invenzione sono riportate di seguito nella descrizione che segue sottoforma di realizzazioni preferite e, pertanto, non limitative della portata della presente invenzione. Preferred forms of the present invention are reported in the following description in the form of preferred embodiments and, therefore, do not limit the scope of the present invention.
La composizione della presente invenzione comprende o, alternativamente, può consistere di una vitamina K2 in associazione con una vitamina D3per uso nel trattamento dell'algodistrofia . The composition of the present invention comprises or, alternatively, may consist of a vitamin K2 in association with a vitamin D3 for use in the treatment of algodystrophy.
In una realizzazione preferita, la composizione della presente invenzione comprende o, alternativamente, può consistere di una vitamina K2, una vitamina D3 e un composto contenente almeno una fonte di calcio e/o magnesio bìodisponibile . In a preferred embodiment, the composition of the present invention comprises or, alternatively, can consist of a vitamin K2, a vitamin D3 and a compound containing at least one source of calcium and / or magnesium readily available.
Vantaggiosamente, detto almeno una fonte di calcio e/o magnesio biodisponibile si ottiene da un'alga Lithothamnium calcareum . Advantageously, said at least one bioavailable source of calcium and / or magnesium is obtained from an alga Lithothamnium calcareum.
Forma un altro oggetto della presente invenzione l'uso di una vitamina K2 in associazione con una vitamina D3per la preparazione di una composizione farmaceutica o integratore o alimentare per il trattamento dell'algodistrofia . Another object of the present invention is the use of a vitamin K2 in association with a vitamin D3 for the preparation of a pharmaceutical or supplement or food composition for the treatment of algodystrophy.
Forma un altro oggetto della presente invenzione l'uso di una vitamina K2, di una vitamina D3e un di composto contenente almeno una fonte di calcio e/o magnesio biodisponibile ottenuto da un'alga Lithothamnium calcareum. La vitamina K2 comprende o, alternativamente, consiste di un composto menachinone- 7 (MK-7) e/o di un composto menachinone- 6 (MK-6), mentre la vitamina D3 e' colecalcif erolo . Another object of the present invention is the use of a vitamin K2, a vitamin D3 and a compound containing at least one bioavailable source of calcium and / or magnesium obtained from an alga Lithothamnium calcareum. Vitamin K2 comprises or, alternatively, consists of a menaquinone-7 compound (MK-7) and / or a menaquinone-6 compound (MK-6), while vitamin D3 is cholecalciferol.
In una realizzazione preferita, dette composizioni comprendono o, alternativamente, consistono del composto menachinone- 7 (MK-7) e/o del composto menachinone-6 (MK-6) in associazione con la vitamina D3(colecalciferolo) . In a preferred embodiment, said compositions comprise or, alternatively, consist of the compound menaquinone-7 (MK-7) and / or of the compound menaquinone-6 (MK-6) in association with vitamin D3 (cholecalciferol).
In un'altra realizzazione preferita, dette composizioni comprendono o, alternativamente, consistono del composto menachinone-7 (MK-7) e/o del composto menachinone-6 (MK-6), della vitamina D3(colecalcif erolo) e di un composto contenente almeno una fonte di calcio e/o magnesio biodisponibile ottenuto da un'alga Lithothamnium calcareum. In un'altra realizzazione preferita, dette composizioni comprendono la vitamina K2 e la vitamina D3 in un rapporto in peso compreso da 3:1 a 20:1, preferibilmente 10:1. Il composto menachinone-7 (MK-7) e il composto menachinone-6 (MK-6) possono essere presenti in dette composizioni in un rapporto in peso compreso da 150:1 a 30:1, preferibilmente da 100:1 a 50:1. In another preferred embodiment, said compositions comprise or, alternatively, consist of the compound menaquinone-7 (MK-7) and / or of the compound menaquinone-6 (MK-6), of vitamin D3 (cholecalciferol) and of a compound containing at least one source of bioavailable calcium and / or magnesium obtained from an algae Lithothamnium calcareum. In another preferred embodiment, said compositions comprise vitamin K2 and vitamin D3 in a weight ratio ranging from 3: 1 to 20: 1, preferably 10: 1. The menaquinone-7 compound (MK-7) and the menaquinone-6 compound (MK-6) can be present in said compositions in a weight ratio ranging from 150: 1 to 30: 1, preferably from 100: 1 to 50: 1.
La composizione della presente invenzione e' in una forma farmaceutica idonea alla somministrazione orale. Ad esempio, può essere sottoforma solida, granulare, polvere o liofilizzata. Preferibilmente, la composizione e' sottoforma di compressa o pastiglia per via orale. The composition of the present invention is in a pharmaceutical form suitable for oral administration. For example, it can be in solid, granular, powder or freeze-dried form. Preferably, the composition is in the form of a tablet or tablet for oral via.
La composizione della presente invenzione può essere indicata per uso farmaceutico, dietetico, nutraceutico o alimentare . The composition of the present invention can be indicated for pharmaceutical, dietetic, nutraceutical or food use.
In una realizzazione preferita, detta composizione consiste di una vitamina K2 , una vitamina D3 e un composto contenente almeno una fonte di calcio e/o magnesio biodisponibile ottenuto da un'alga Lithothamnium calcareum. In una realizzazione preferita, detta composizione comprende o, alternativamente, consiste di una vitamina K2, una vitamina D3;e un composto contenente almeno una fonte di calcio e/o magnesio biodisponibile ottenuto da un'alga Lìthothamnium calcareum, in accordo ad una o piu' delle realizzazioni precedenti, per uso come antidolorifico nel trattamento curativo dell'algodistrofia. In a preferred embodiment, said composition consists of a vitamin K2, a vitamin D3 and a compound containing at least one source of bioavailable calcium and / or magnesium obtained from an alga Lithothamnium calcareum. In a preferred embodiment, said composition comprises or, alternatively, consists of a vitamin K2, a vitamin D3; and a compound containing at least one source of bioavailable calcium and / or magnesium obtained from an alga Lìthothamnium calcareum, according to a or more of the previous realizations, for use as a pain reliever in the curative treatment of algodystrophy.
La Richiedente ha trovato che il composto menachinone-7 (MK-7) e il composto menachinone-6 (MK-6) assicurano un'elevata mineralizzazione dell'osso fratturato, mentre la vitamina D3 e' utile per l'assorbimento intestinale del calcio il quale viene fissato a livello osseo. The Applicant has found that the compound menaquinone-7 (MK-7) and the compound menaquinone-6 (MK-6) ensure a high mineralization of the fractured bone, while vitamin D3 is useful for intestinal absorption of calcium. which is fixed at the bone level.
La Richiedente ha trovato che l'associazione della vitamina K2, in particolare del composto menachinone-7, e della vitamina D3 con il composto contenente almeno una fonte di calcio e/o magnesio biodisponibile ottenuto da un'alga Lìthothamnium Calcareum consente, vantaggiosamente, una corretta mineralizzazione ossea. La presenza della vitamina D3 favorisce l'assorbimento e la fissazione a livello osseo del calcio presente, in una forma altamente biodisponibile, in detta composizione. Il calcio e il magnesio di origine aigaie derivano da alghe calcificate della specie Lithothamnion Calcareum. Grazie alla loro microstruttura cosiddetta "ad alveare", il calcio e/o il magnesio sono altamente biodisponibile e ben tollerati a livello gastrointestinale. I sali minerali organici di cui l'alga à ̈ costituita favoriscono la sintesi del collagene e dell'elastina e stimolano le cellule osteopoiet iche, indispensabili per la formazione delle ossa e per mantenere 1 'elasticita'del tessuto connettivo. The Applicant has found that the association of vitamin K2, in particular of the menaquinone-7 compound, and of vitamin D3 with the compound containing at least one source of bioavailable calcium and / or magnesium obtained from an alga Lìthothamnium Calcareum, advantageously , proper bone mineralization. The presence of vitamin D3 favors the absorption and fixation at the bone level of the calcium present, in a highly bioavailable form, in said composition. Calcium and magnesium of aigaie origin derive from calcified algae of the Lithothamnion Calcareum species. Thanks to their so-called "beehive" microstructure, calcium and / or magnesium are highly bioavailable and well tolerated in the gastrointestinal tract. The organic mineral salts of which the alga is made up favor the synthesis of collagen and elastin and stimulate the osteopoietic cells, essential for the formation of bones and to maintain the elasticity of the connective tissue.
La composizione della presente invenzione consente di ridurre il dolore, provocato dall'algodistrofia, e al tempo stesso di dare origine a una corretta mineralizzazione dell'osso. Pertanto, la composizione della presente invenzione à ̈ in grado, in maniera vantaggiosa, di contribuire ai processi di mineralizzazione dell'osso che ha subito il trauma e di conseguneza à ̈ in grado di contribuire, in maniera determinante, alla calcificazione dell'osso. Inoltre, la composizione della presente invenzione, oltre che a contribuire ai processi di mineralizzazione dell'osso, à ̈ in grado in maniera vantaggiosa di ridurre/eliminare il dolore originato da una demineralizzazione dell'osso. L'assunzione da parte di un soggetto che ha subito un trauma, ad esempio una frattura o una distorsione del piede, caviglia o polso, di una composizione comprendente o consistente di una vitamina K2 in associazione con una vitamina D3 e un composto in grado di rilasciare calcio e/o magnesio ha il vantaggio di ridurre/eliminare completamente l'assunzione di farmaci antidolorifici non steroidei (FANS). The composition of the present invention allows to reduce the pain caused by algodystrophy, and at the same time to give rise to a correct mineralization of the bone. Therefore, the composition of the present invention is able, in an advantageous way, to contribute to the mineralization processes of the bone that has undergone the trauma and consequently is able to contribute, in a decisive way, to the calcification of the bone. Furthermore, the composition of the present invention, in addition to contributing to the bone mineralization processes, is able to advantageously reduce / eliminate the pain originating from bone demineralization. The intake by a person who has suffered a trauma, for example a fracture or a sprain of the foot, ankle or wrist, of a composition comprising or consisting of a vitamin K2 in association with a vitamin D3 and a compound capable of releasing calcium and / or magnesium has the advantage of completely reducing / eliminating the intake of non-steroidal pain relievers (NSAIDs).
Ad esempio, senza voler limitare in alcun modo la portata della presente invenzione, una dose giornaliera in bustina da 5 grammi può'contenere: 3,33 g di un composto contenente almeno una fonte di calcio e/o magnesio biodisponibile ottenuto da un'alga Lithothamnium Calcareum, di cui il calcio biodisponibile e' 400,00 mg (50% RDA) e il magnesio biodisponibile e' 33 mg; vitamina D3 10,000 mcg (200% RDA); vitamina K2 (menachinone-7 e/o menachinone-6) 45,00 mcg; eccipienti e coformulanti accettabili. For example, without wishing to limit in any way the scope of the present invention, a daily dose in a 5 gram sachet can contain: 3.33 g of a compound containing at least one source of bioavailable calcium and / or magnesium obtained from an alga Lithothamnium Calcareum, of which the bioavailable calcium is 400.00 mg (50% RDA) and the bioavailable magnesium is 33 mg; vitamin D3 10,000 mcg (200% RDA); vitamin K2 (menaquinone-7 and / or menaquinone-6) 45.00 mcg; acceptable excipients and co-formulants.
La composizione della presente invenzione contiene dal 5 al 15% in peso, rispetto al peso totale, di un composto contenente almeno una fonte di calcio e/o magnesio biodisponibile ottenuto da un'alga Lithothamnium Calcareum; preferibilmente da 7 a 10%, in peso. The composition of the present invention contains from 5 to 15% by weight, with respect to the total weight, of a compound containing at least one source of bioavailable calcium and / or magnesium obtained from an alga Lithothamnium Calcareum; preferably from 7 to 10% by weight.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000771A ITMI20110771A1 (en) | 2011-05-06 | 2011-05-06 | COMPOSITION INCLUDING AN ASSOCIATION OF VITAMINS FOR USE IN THE TREATMENT OF ALGODISTROFIA. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000771A ITMI20110771A1 (en) | 2011-05-06 | 2011-05-06 | COMPOSITION INCLUDING AN ASSOCIATION OF VITAMINS FOR USE IN THE TREATMENT OF ALGODISTROFIA. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ITMI20110771A1 true ITMI20110771A1 (en) | 2012-11-07 |
Family
ID=44554461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT000771A ITMI20110771A1 (en) | 2011-05-06 | 2011-05-06 | COMPOSITION INCLUDING AN ASSOCIATION OF VITAMINS FOR USE IN THE TREATMENT OF ALGODISTROFIA. |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | ITMI20110771A1 (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1433388A1 (en) * | 2002-12-23 | 2004-06-30 | Laboratoires Thalgo Nutrition | Algae-based food supplement |
| BE1016895A6 (en) * | 2005-12-16 | 2007-09-04 | Psaltopoulos Emmanuel | Calcium composition, useful to prevent/treat osteoporosis and articular cartilage calcification, comprises optionally elementary calcium in the form e.g. of calcium carbonate or calcium citrate, and vitamins e.g. vitamin-D3, vitamin-K3 |
| US20080220094A1 (en) * | 2006-11-01 | 2008-09-11 | Wyeth | Compositions and methods for the treatment and/or prevention of osteoporosis |
| WO2009095798A2 (en) * | 2008-01-28 | 2009-08-06 | Beauty Pearl Group Limited | Formulas comprising calcium, magnesium, zinc, and vitamin d3 for the prevention and amelioration of osteoporosis |
| US20100278940A1 (en) * | 2005-04-04 | 2010-11-04 | Hl Distribution Company | Calcium supplements |
| WO2011089531A2 (en) * | 2010-05-07 | 2011-07-28 | Pharmanutra S.R.L. | Effects of the association of vitamin k2 and vitamin d3 in the consolidation of a bone fracture |
-
2011
- 2011-05-06 IT IT000771A patent/ITMI20110771A1/en unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1433388A1 (en) * | 2002-12-23 | 2004-06-30 | Laboratoires Thalgo Nutrition | Algae-based food supplement |
| US20100278940A1 (en) * | 2005-04-04 | 2010-11-04 | Hl Distribution Company | Calcium supplements |
| BE1016895A6 (en) * | 2005-12-16 | 2007-09-04 | Psaltopoulos Emmanuel | Calcium composition, useful to prevent/treat osteoporosis and articular cartilage calcification, comprises optionally elementary calcium in the form e.g. of calcium carbonate or calcium citrate, and vitamins e.g. vitamin-D3, vitamin-K3 |
| US20080220094A1 (en) * | 2006-11-01 | 2008-09-11 | Wyeth | Compositions and methods for the treatment and/or prevention of osteoporosis |
| WO2009095798A2 (en) * | 2008-01-28 | 2009-08-06 | Beauty Pearl Group Limited | Formulas comprising calcium, magnesium, zinc, and vitamin d3 for the prevention and amelioration of osteoporosis |
| WO2011089531A2 (en) * | 2010-05-07 | 2011-07-28 | Pharmanutra S.R.L. | Effects of the association of vitamin k2 and vitamin d3 in the consolidation of a bone fracture |
Non-Patent Citations (3)
| Title |
|---|
| CHAUVINEAU V ET AL: "[What is the place of diphosphonates in the treatment of complex regional pain syndrome I?].", April 2005, ANNALES DE RÉADAPTATION ET DE MÉDECINE PHYSIQUE : REVUE SCIENTIFIQUE DE LA SOCIÉTÉ FRANÇAISE DE RÉÉDUCATION FONCTIONNELLE DE RÉADAPTATION ET DE MÉDECINE PHYSIQUE APR 2005 LNKD- PUBMED:15833263, VOL. 48, NR. 3, PAGE(S) 150 - 157, ISSN: 0168-6054, XP002660796 * |
| MUHAMMAD NADEEM ASLAM ET AL: "A Mineral-Rich Extract from the Red Marine Algae Lithothamnion calcareum Preserves Bone Structure and Function in Female Mice on a Western-Style Diet", CALCIFIED TISSUE INTERNATIONAL, SPRINGER-VERLAG, NE, vol. 86, no. 4, 24 February 2010 (2010-02-24), pages 313 - 324, XP019799211, ISSN: 1432-0827 * |
| SMITH E J ET AL: "Post-traumatic osteoporosis and algodystrophy after external fixation of tibial fractures", INJURY, JOHN WRIGHT AND SONS, BRISTOL, GB, vol. 24, no. 6, 1 July 1993 (1993-07-01), pages 411 - 415, XP026455144, ISSN: 0020-1383, [retrieved on 19930701] * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2848552T3 (en) | Compositions to stimulate bone growth | |
| ES2880618T3 (en) | Transmucosal and transdermal delivery systems | |
| ES2878017T3 (en) | Porous silica material for use as a pharmaceutical or dietary active ingredient | |
| ES2555166B1 (en) | Compositions of phytic acid, magnesium and polyphenols and their application for the prevention of oxaloccalcic renal lithiasis | |
| US6887497B2 (en) | Composition for the treatment and prevention of osteoarthritis, rheumatoid arthritis and improved joint function | |
| CA2982645C (en) | Composition for suppressing muscular fatty change | |
| JP2011510922A5 (en) | ||
| EA201401155A1 (en) | PREPARATION AND METHOD OF PREVENTION AND TREATMENT OF ATYPICAL OSTEOPOROSIS | |
| ITMI20110771A1 (en) | COMPOSITION INCLUDING AN ASSOCIATION OF VITAMINS FOR USE IN THE TREATMENT OF ALGODISTROFIA. | |
| US9801905B2 (en) | Use of organic sulphur, antioxidants, and amino acids in conjunction with exercise and electromagnetic stimulation to treat osteoporosis | |
| ES2795104T3 (en) | Plant phenols and their use in the treatment or prevention of eosinophilic esophagitis | |
| AU2012377478A8 (en) | Preparation and method for the prophylaxis and treatment of osteoporosis and bone fractures | |
| AU2014322996B2 (en) | Cocoa polyphenols and their use in the treatment or prevention of eosinophilic esophagitis | |
| Oršolić | Bee honey and cancer | |
| BR112012011316A2 (en) | tivozanib and temsirolimus in combination | |
| RU2010125505A (en) | PHARMACEUTICAL SET FROM EMULSION TYPE "OIL IN WATER" AND SOLID COMPOSITION | |
| RU2268053C1 (en) | Method for treating hypocalcemia, osteoporosis , fractures | |
| Mukhopadhyay et al. | A Review on change in chemical, morphological and therapeutic activity of honey | |
| RO130486B1 (en) | Pharmaceutical formula for chewable minted tablets with calcium and vitamin d3 content | |
| DONATO | FOOD SOURCES | |
| UA119715U (en) | APISAN GEL FOR LOCAL PREVENTION AND TREATMENT OF TRAUMATIC MUSCULAR INJURY | |
| WO2012082013A3 (en) | Pharmaceutical composition for stimulating the regeneration of supporting tissue and articular cartilage (variants) | |
| CZ22065U1 (en) | Food supplement enhancing protection of lower urinary tract epithelium from repeated infections |